PE-22-28 is described in peer-reviewed research as a seven-residue shortened spadin analogue. Buyers should control the exact GVSWGLR sequence and distinguish it from PE-12-28, modified analogues and unrelated PE-numbered materials.
Direct answer for Google and AI search
A technical sourcing guide for PE-22-28 research peptide covering the GVSWGLR sequence, spadin-analogue naming, terminal and counterion form, identity, purity and lot control. The useful decision is not a simple yes-or-no claim; it is whether the named material, batch evidence, method scope and supplier responsibility match the buyer's research requirement.
Users may ask
- How should a buyer evaluate PE-22-28?
- What data should a peptide supplier provide for peptide chemistry & forms?
- Does the offer match unmodified GVSWGLR?
- Which counterion and quantity basis apply?
- Can the method distinguish shortened or modified analogues?
Key parameters
- Primary intent
- PE-22-28 peptide supplier China
- Product focus
- PE-22-28
- Page type
- technical procurement answer
- Evidence boundary
- Peptide Chemistry & Forms
- Required next step
- confirm lot, method, specification and project scope
This answer supports education, procurement comparison and laboratory research sourcing. It does not imply human benefits, dosage, injection guidance, treatment claims or approval for clinical, diagnostic or veterinary use.
What procurement and laboratory teams should review
Specify GVSWGLR and terminal chemistry
Separate PE-22-28 from spadin and modified analogues
State TFA, acetate or other counterion form
Use lot-specific HPLC, MS and content evidence
Define the molecular form before comparing offers
Sequence alone may not fully define a peptide material. Termini, modifications, disulfide pattern, counterion, hydration state and presentation can affect molecular-weight calculations, analytical reporting, solubility and handling.
- Record sequence, termini and every modification explicitly.
- State the requested salt or counterion form.
- Treat solubility and stability as material- and condition-specific.
Control the seven-residue target
The primary research describes PE-22-28 among shortened spadin analogues and examines terminal modifications separately. The RFQ should therefore state GVSWGLR, terminal groups and whether the target is unmodified, rather than using PE-22-28 as the only identity field.
An observed mass should be evaluated against the correct molecular and ion form. HPLC reports a method-specific related-peptide profile, while content, water and counterion require separate measurements or calculations.
Keep model findings out of supplier promises
Published results concern defined in-vitro assays and animal models. They do not establish clinical safety, approved use or effects for a third-party research lot. Supplier content should explain evidence boundaries instead of repeating consumer claims.
- GVSWGLR sequence
- Terminal and counterion form
- Lot-specific MS and HPLC
- No clinical extrapolation
Questions to resolve before quotation or release
- Does the offer match unmodified GVSWGLR?
- Which counterion and quantity basis apply?
- Can the method distinguish shortened or modified analogues?
HK PEPTIDES PE-22-28 is offered only for controlled laboratory research, without neurological, behavioral, dosing, treatment or human-use claims.
Frequently asked questions
Is PE-22-28 the same as full-length spadin?
No. PE-22-28 is a shortened seven-residue analogue and should be specified separately.
Does PE-22-28 research establish human effects?
No. The cited work is preclinical and does not establish approved human use.
Source material and further reading
This guide is informed by the following primary guidance and established technical resources. Always confirm the current version and its applicability to your material and jurisdiction.
HK PEPTIDES materials are supplied for laboratory research and documentation workflows only. They are not intended for human consumption, diagnostic use, therapeutic use, veterinary use or clinical application.